Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial

The aim of this study was to explore the efficacy and safety of obinutuzumab (G)- versus rituximab (R)-chemotherapy in a subgroup of patients with previously untreated marginal zone lymphoma (MZL) in the phase III GALLIUM trial (NCT01332968). Patients had stage III/IV (or stage II with bulky disease...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Michael Herold, Eva Hoster, Ann Janssens, Helen McCarthy, Alessandra Tedeschi, Chris Pocock, Andras Rosta, Marek Trněný, Tina G. Nielsen, Andrea Knapp, Wolfgang Hiddemann, Robert Marcus
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Wiley 2022-03-01
סדרה:	HemaSphere
גישה מקוונת:	http://journals.lww.com/10.1097/HS9.0000000000000699
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!